Eric Jourdan
0000-0003-3083-6653
Institut de Cancérologie du Gard
2 papers found
Refreshing results…
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis
Interim PET Response-adapted Strategy in Untreated Advanced Stage Hodgkin Lymphoma: Results of GOELAMS LH 2007 Phase 2 Multicentric Trial
Missing publications? Search for publications with a matching author name.